Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Hinge Health, Inc.HNGE · Entity 377 | President | October 01, 2026 | October 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Hinge Health, Inc.
Report date October 01, 2026 · Filed October 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 666,078 |
Reported balance
After 2026-10-01 transaction · row 1
1 source rowRow 1 · 2026-10-01 · Tax withholding · Disposed 831 · Balance 666,078 F1: Exempt transaction pursuant to Section 16b-3(e) - payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3. All of the shares reported as disposed of in this Form 4 were relinquished by the Reporting Person and cancelled by the Issuer in exchange for the Issuer's agreement to pay federal and state tax withholding obligations of the Reporting Person resulting from the vesting of restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Exempt transaction pursuant to Section 16b-3(e) - payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3. All of the shares reported as disposed of in this Form 4 were relinquished by the Reporting Person and cancelled by the Issuer in exchange for the Issuer's agreement to pay federal and state tax withholding obligations of the Reporting Person resulting from the vesting of restricted stock units.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Livongo Health, Inc.
Report date October 30, 2020 · Filed October 30, 2020
Section 16 reporting ended · disclosed 2020-10-30. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-10-30 transaction · row 1
1 source rowRow 1 · 2020-10-30 · Disposition to issuer · Disposed 73,294 · Balance 0 F1: Includes 21,537 restricted stock units ("RSUs"). F2: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 5, 2020, by and among the Issuer, Teladoc Health, Inc. ("Teladoc"), and Tempranillo Merger Sub, Inc., a wholly owned subsidiary of Teladoc, each share of the Issuer's common stock was converted into the right to receive 0.5920 of a share of Teladoc common stock and $4.24 in cash, without interest, together with cash in lieu of fractional shares (if any). F3: Pursuant to the Merger Agreement, each outstanding RSU award of the Issuer was converted into a number of RSUs with respect to a number of shares of Teladoc common stock equal to the product of (i) the number of shares of the Issuer's common stock subject to such RSU award immediately prior to the effective time of the merger and (ii) the Equity Award Adjustment Ratio (as defined below) (rounded down to the nearest whole share of Teladoc common stock on an award-by-award basis), subject to the same terms and conditions as were applicable to such Issuer RSU immediately prior to the effective time of the merger (including applicable vesting conditions). F4: The "Equity Award Adjustment Ratio" means the quotient determined by dividing (i) the volume weighted average closing price of the Issuer's common stock on the four trading days ending on October 29, 2020 by (ii) the volume weighted average closing price of Teladoc common stock on the four trading days beginning on October 29, 2020. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.80 · Expires 2025-12-10 | Direct | 0 |
Reported balance
After 2020-10-30 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-10-30 · Disposition to issuer · Disposed 105,572 · Balance 0 F4: The "Equity Award Adjustment Ratio" means the quotient determined by dividing (i) the volume weighted average closing price of the Issuer's common stock on the four trading days ending on October 29, 2020 by (ii) the volume weighted average closing price of Teladoc common stock on the four trading days beginning on October 29, 2020. F6: Pursuant to the Merger Agreement, each outstanding stock option of the Issuer, whether vested or unvested, was converted into an option to purchase a number of shares of Teladoc common stock equal to the product of (i) the number of shares of the Issuer's common stock subject to such Issuer stock option immediately prior to the effective time of the merger and (ii) the Equity Award Adjustment Ratio (rounded down to the nearest whole share of Teladoc common stock on an award-by-award basis), with an exercise price equal to the quotient of (x) the exercise price of such Issuer stock option and (y) the Equity Award Adjustment Ratio (rounded up to the nearest whole cent), subject to the same terms and conditions as were applicable to such Issuer stock option immediately prior to the effective time of the merger (including applicable vesting conditions). F5: Shares subject to the option are fully vested and immediately exercisable. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.80 · Expires 2026-02-17 | Direct | 0 |
Reported balance
After 2020-10-30 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-10-30 · Disposition to issuer · Disposed 50,000 · Balance 0 F4: The "Equity Award Adjustment Ratio" means the quotient determined by dividing (i) the volume weighted average closing price of the Issuer's common stock on the four trading days ending on October 29, 2020 by (ii) the volume weighted average closing price of Teladoc common stock on the four trading days beginning on October 29, 2020. F6: Pursuant to the Merger Agreement, each outstanding stock option of the Issuer, whether vested or unvested, was converted into an option to purchase a number of shares of Teladoc common stock equal to the product of (i) the number of shares of the Issuer's common stock subject to such Issuer stock option immediately prior to the effective time of the merger and (ii) the Equity Award Adjustment Ratio (rounded down to the nearest whole share of Teladoc common stock on an award-by-award basis), with an exercise price equal to the quotient of (x) the exercise price of such Issuer stock option and (y) the Equity Award Adjustment Ratio (rounded up to the nearest whole cent), subject to the same terms and conditions as were applicable to such Issuer stock option immediately prior to the effective time of the merger (including applicable vesting conditions). F5: Shares subject to the option are fully vested and immediately exercisable. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.38 · Expires 2026-11-15 | Direct | 0 |
Reported balance
After 2020-10-30 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-10-30 · Disposition to issuer · Disposed 125,000 · Balance 0 F4: The "Equity Award Adjustment Ratio" means the quotient determined by dividing (i) the volume weighted average closing price of the Issuer's common stock on the four trading days ending on October 29, 2020 by (ii) the volume weighted average closing price of Teladoc common stock on the four trading days beginning on October 29, 2020. F6: Pursuant to the Merger Agreement, each outstanding stock option of the Issuer, whether vested or unvested, was converted into an option to purchase a number of shares of Teladoc common stock equal to the product of (i) the number of shares of the Issuer's common stock subject to such Issuer stock option immediately prior to the effective time of the merger and (ii) the Equity Award Adjustment Ratio (rounded down to the nearest whole share of Teladoc common stock on an award-by-award basis), with an exercise price equal to the quotient of (x) the exercise price of such Issuer stock option and (y) the Equity Award Adjustment Ratio (rounded up to the nearest whole cent), subject to the same terms and conditions as were applicable to such Issuer stock option immediately prior to the effective time of the merger (including applicable vesting conditions). F7: One-fourth of the shares subject to the option vested on November 16, 2017 and 1/48 of the shares vest monthly thereafter. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.88 · Expires 2027-12-03 | Direct | 0 |
Reported balance
After 2020-10-30 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-10-30 · Disposition to issuer · Disposed 120,000 · Balance 0 F4: The "Equity Award Adjustment Ratio" means the quotient determined by dividing (i) the volume weighted average closing price of the Issuer's common stock on the four trading days ending on October 29, 2020 by (ii) the volume weighted average closing price of Teladoc common stock on the four trading days beginning on October 29, 2020. F6: Pursuant to the Merger Agreement, each outstanding stock option of the Issuer, whether vested or unvested, was converted into an option to purchase a number of shares of Teladoc common stock equal to the product of (i) the number of shares of the Issuer's common stock subject to such Issuer stock option immediately prior to the effective time of the merger and (ii) the Equity Award Adjustment Ratio (rounded down to the nearest whole share of Teladoc common stock on an award-by-award basis), with an exercise price equal to the quotient of (x) the exercise price of such Issuer stock option and (y) the Equity Award Adjustment Ratio (rounded up to the nearest whole cent), subject to the same terms and conditions as were applicable to such Issuer stock option immediately prior to the effective time of the merger (including applicable vesting conditions). F8: One-fourth of the shares subject to the option vested on December 4, 2018 and 1/48 of the shares vest monthly thereafter. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.62 · Expires 2028-06-18 | Direct | 0 |
Reported balance
After 2020-10-30 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-10-30 · Disposition to issuer · Disposed 100,000 · Balance 0 F4: The "Equity Award Adjustment Ratio" means the quotient determined by dividing (i) the volume weighted average closing price of the Issuer's common stock on the four trading days ending on October 29, 2020 by (ii) the volume weighted average closing price of Teladoc common stock on the four trading days beginning on October 29, 2020. F6: Pursuant to the Merger Agreement, each outstanding stock option of the Issuer, whether vested or unvested, was converted into an option to purchase a number of shares of Teladoc common stock equal to the product of (i) the number of shares of the Issuer's common stock subject to such Issuer stock option immediately prior to the effective time of the merger and (ii) the Equity Award Adjustment Ratio (rounded down to the nearest whole share of Teladoc common stock on an award-by-award basis), with an exercise price equal to the quotient of (x) the exercise price of such Issuer stock option and (y) the Equity Award Adjustment Ratio (rounded up to the nearest whole cent), subject to the same terms and conditions as were applicable to such Issuer stock option immediately prior to the effective time of the merger (including applicable vesting conditions). F9: One-fourth of the shares subject to the option vested on June 19, 2019 and 1/48 of the shares vest monthly thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 21,537 restricted stock units ("RSUs").
F2: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 5, 2020, by and among the Issuer, Teladoc Health, Inc. ("Teladoc"), and Tempranillo Merger Sub, Inc., a wholly owned subsidiary of Teladoc, each share of the Issuer's common stock was converted into the right to receive 0.5920 of a share of Teladoc common stock and $4.24 in cash, without interest, together with cash in lieu of fractional shares (if any).
F3: Pursuant to the Merger Agreement, each outstanding RSU award of the Issuer was converted into a number of RSUs with respect to a number of shares of Teladoc common stock equal to the product of (i) the number of shares of the Issuer's common stock subject to such RSU award immediately prior to the effective time of the merger and (ii) the Equity Award Adjustment Ratio (as defined below) (rounded down to the nearest whole share of Teladoc common stock on an award-by-award basis), subject to the same terms and conditions as were applicable to such Issuer RSU immediately prior to the effective time of the merger (including applicable vesting conditions).
F4: The "Equity Award Adjustment Ratio" means the quotient determined by dividing (i) the volume weighted average closing price of the Issuer's common stock on the four trading days ending on October 29, 2020 by (ii) the volume weighted average closing price of Teladoc common stock on the four trading days beginning on October 29, 2020.
F5: Shares subject to the option are fully vested and immediately exercisable.
F6: Pursuant to the Merger Agreement, each outstanding stock option of the Issuer, whether vested or unvested, was converted into an option to purchase a number of shares of Teladoc common stock equal to the product of (i) the number of shares of the Issuer's common stock subject to such Issuer stock option immediately prior to the effective time of the merger and (ii) the Equity Award Adjustment Ratio (rounded down to the nearest whole share of Teladoc common stock on an award-by-award basis), with an exercise price equal to the quotient of (x) the exercise price of such Issuer stock option and (y) the Equity Award Adjustment Ratio (rounded up to the nearest whole cent), subject to the same terms and conditions as were applicable to such Issuer stock option immediately prior to the effective time of the merger (including applicable vesting conditions).
F7: One-fourth of the shares subject to the option vested on November 16, 2017 and 1/48 of the shares vest monthly thereafter.
F8: One-fourth of the shares subject to the option vested on December 4, 2018 and 1/48 of the shares vest monthly thereafter.
F9: One-fourth of the shares subject to the option vested on June 19, 2019 and 1/48 of the shares vest monthly thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 01, 2026 Filed Oct 2, 2026 02:49 UTC | Hinge Health, Inc. HNGE · Entity 377 | Tax withholdingClass A Common Stock | 831 | $97.24 | $80,806.44 |
DisclosureSEC source: 0001783108-26-000034 · form4-10012026_101004.xml · nonDerivative · entry 1 Pursley James · CIK 0001783108 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 666,078 F1 · kind: Exempt transaction pursuant to Section 16b-3(e) - payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3. All of the shares reported as disposed of in this Form 4 were relinquished by the Reporting Person and cancelled by the Issuer in exchange for the Issuer's agreement to pay federal and state tax withholding obligations of the Reporting Person resulting from the vesting of restricted stock units. Read SEC document |
| September 21, 2026 Filed Sep 23, 2026 21:07 UTC | Hinge Health, Inc. HNGE · Entity 377 | SaleClass A Common Stock | 800 | $95.10 | $76,077.44 |
DisclosureSEC source: 0001783108-26-000032 · form4-09232026_090954.xml · nonDerivative · entry 3 Pursley James · CIK 0001783108 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 666,909 F1 · kind: The sales reported in this line item were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2026. F4 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $94.94 and the highest price at which shares were sold was $95.51. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. Read SEC document |
| September 21, 2026 Filed Sep 23, 2026 21:07 UTC | Hinge Health, Inc. HNGE · Entity 377 | SaleClass A Common Stock | 23,135 | $94.40 | $2,184,045.79 |
DisclosureSEC source: 0001783108-26-000032 · form4-09232026_090954.xml · nonDerivative · entry 2 Pursley James · CIK 0001783108 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 667,709 F1 · kind: The sales reported in this line item were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2026. F3 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $93.93 and the highest price at which shares were sold was $94.92. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. Read SEC document |
| September 21, 2026 Filed Sep 23, 2026 21:07 UTC | Hinge Health, Inc. HNGE · Entity 377 | SaleClass A Common Stock | 9,065 | $93.37 | $846,380.92 |
DisclosureSEC source: 0001783108-26-000032 · form4-09232026_090954.xml · nonDerivative · entry 1 Pursley James · CIK 0001783108 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 690,844 F1 · kind: The sales reported in this line item were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2026. F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $92.93 and the highest price at which shares were sold was $93.92. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. Read SEC document |
| September 01, 2026 Filed Sep 2, 2026 20:14 UTC | Hinge Health, Inc. HNGE · Entity 377 | Tax withholdingClass A Common Stock | 6,326 | $92.56 | $585,534.56 |
DisclosureSEC source: 0001783108-26-000030 · form4-09022026_080959.xml · nonDerivative · entry 1 Pursley James · CIK 0001783108 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 699,909 F1 · kind: Exempt transaction pursuant to Section 16b-3(e) - payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3. All of the shares reported as disposed of in this Form 4 were relinquished by the Reporting Person and cancelled by the Issuer in exchange for the Issuer's agreement to pay federal and state tax withholding obligations of the Reporting Person resulting from the vesting of restricted stock units. Read SEC document |
| August 21, 2026 Filed Aug 24, 2026 21:31 UTC | Hinge Health, Inc. HNGE · Entity 377 | SaleClass A Common Stock | 3,411 | $88.68 | $302,491.91 |
DisclosureSEC source: 0001783108-26-000028 · form4-08242026_090832.xml · nonDerivative · entry 4 Pursley James · CIK 0001783108 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 706,235 F1 · kind: The sales reported in this line item were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 13, 2025. F5 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $88.58 and the highest price at which shares were sold was $88.94. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. Read SEC document |
| August 21, 2026 Filed Aug 24, 2026 21:31 UTC | Hinge Health, Inc. HNGE · Entity 377 | SaleClass A Common Stock | 22,789 | $88.25 | $2,011,211.29 |
DisclosureSEC source: 0001783108-26-000028 · form4-08242026_090832.xml · nonDerivative · entry 3 Pursley James · CIK 0001783108 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 709,646 F1 · kind: The sales reported in this line item were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 13, 2025. F4 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $87.58 and the highest price at which shares were sold was $88.575. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. Read SEC document |
| August 21, 2026 Filed Aug 24, 2026 21:31 UTC | Hinge Health, Inc. HNGE · Entity 377 | SaleClass A Common Stock | 6,300 | $87.23 | $549,559.08 |
DisclosureSEC source: 0001783108-26-000028 · form4-08242026_090832.xml · nonDerivative · entry 2 Pursley James · CIK 0001783108 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 732,435 F1 · kind: The sales reported in this line item were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 13, 2025. F3 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $86.57 and the highest price at which shares were sold was $87.56. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. Read SEC document |
| August 21, 2026 Filed Aug 24, 2026 21:31 UTC | Hinge Health, Inc. HNGE · Entity 377 | SaleClass A Common Stock | 500 | $84.80 | $42,401.00 |
DisclosureSEC source: 0001783108-26-000028 · form4-08242026_090832.xml · nonDerivative · entry 1 Pursley James · CIK 0001783108 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 738,735 F1 · kind: The sales reported in this line item were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 13, 2025. F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $84.65 and the highest price at which shares were sold was $85.03. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. Read SEC document |
| August 01, 2026 Filed Aug 4, 2026 22:48 UTC | Hinge Health, Inc. HNGE · Entity 377 | Tax withholdingClass A Common Stock | 831 | $74.71 | $62,084.01 |
DisclosureSEC source: 0001783108-26-000026 · form4-08042026_100857.xml · nonDerivative · entry 1 Pursley James · CIK 0001783108 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 739,235 F1 · kind: Exempt transaction pursuant to Section 16b-3(e) - payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3. All of the shares reported as disposed of in this Form 4 were relinquished by the Reporting Person and cancelled by the Issuer in exchange for the Issuer's agreement to pay federal and state tax withholding obligations of the Reporting Person resulting from the vesting of restricted stock units. Read SEC document |
| July 01, 2026 Filed Jul 2, 2026 20:40 UTC | Hinge Health, Inc. HNGE · Entity 377 | Tax withholdingClass A Common Stock | 831 | $83.00 | $68,973.00 |
DisclosureSEC source: 0001783108-26-000024 · form4-07022026_080713.xml · nonDerivative · entry 1 Pursley James · CIK 0001783108 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 740,066 F1 · kind: Exempt transaction pursuant to Section 16b-3(e) - payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3. All of the shares reported as disposed of in this Form 4 were relinquished by the Reporting Person and cancelled by the Issuer in exchange for the Issuer's agreement to pay federal and state tax withholding obligations of the Reporting Person resulting from the vesting of restricted stock units. Read SEC document |
| June 22, 2026 Filed Jun 23, 2026 20:52 UTC | Hinge Health, Inc. HNGE · Entity 377 | SaleClass A Common Stock | 2,558 | $70.89 | $181,336.62 |
DisclosureSEC source: 0001783108-26-000022 · form4-06232026_080631.xml · nonDerivative · entry 3 Pursley James · CIK 0001783108 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 740,897 F1 · kind: The sales reported in this line item were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 13, 2025. F4 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $70.36 and the highest price at which shares were sold was $71.34. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. Read SEC document |
| June 22, 2026 Filed Jun 23, 2026 20:52 UTC | Hinge Health, Inc. HNGE · Entity 377 | SaleClass A Common Stock | 8,507 | $69.82 | $593,998.72 |
DisclosureSEC source: 0001783108-26-000022 · form4-06232026_080631.xml · nonDerivative · entry 2 Pursley James · CIK 0001783108 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 743,455 F1 · kind: The sales reported in this line item were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 13, 2025. F3 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $69.35 and the highest price at which shares were sold was $70.345. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. Read SEC document |
| June 22, 2026 Filed Jun 23, 2026 20:52 UTC | Hinge Health, Inc. HNGE · Entity 377 | SaleClass A Common Stock | 21,935 | $68.93 | $1,511,915.94 |
DisclosureSEC source: 0001783108-26-000022 · form4-06232026_080631.xml · nonDerivative · entry 1 Pursley James · CIK 0001783108 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 751,962 F1 · kind: The sales reported in this line item were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 13, 2025. F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $68.35 and the highest price at which shares were sold was $69.34. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. Read SEC document |
| June 01, 2026 Filed Jun 1, 2026 23:10 UTC | Hinge Health, Inc. HNGE · Entity 377 | Tax withholdingClass A Common Stock | 6,326 | $56.21 | $355,584.46 |
DisclosureSEC source: 0001783108-26-000020 · form4-06012026_110640.xml · nonDerivative · entry 1 Pursley James · CIK 0001783108 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 773,897 F1 · kind: Exempt transaction pursuant to Section 16b-3(e) - payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3. All of the shares reported as disposed of in this Form 4 were relinquished by the Reporting Person and cancelled by the Issuer in exchange for the Issuer's agreement to pay federal and state tax withholding obligations of the Reporting Person resulting from the vesting of restricted stock units. Read SEC document |
| May 26, 2026 Filed May 27, 2026 23:14 UTC | Hinge Health, Inc. HNGE · Entity 377 | SaleClass A Common Stock | 1,100 | $55.16 | $60,673.14 |
DisclosureSEC source: 0001783108-26-000018 · form4-05272026_110553.xml · nonDerivative · entry 3 Pursley James · CIK 0001783108 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 780,223 F1 · kind: The sales reported in this line item were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 13, 2025. F5 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $54.86 and the highest price at which shares were sold was $55.43. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. Read SEC document |
| May 26, 2026 Filed May 27, 2026 23:14 UTC | Hinge Health, Inc. HNGE · Entity 377 | SaleClass A Common Stock | 5,905 | $54.29 | $320,564.74 |
DisclosureSEC source: 0001783108-26-000018 · form4-05272026_110553.xml · nonDerivative · entry 2 Pursley James · CIK 0001783108 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 781,323 F1 · kind: The sales reported in this line item were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 13, 2025. F4 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $53.85 and the highest price at which shares were sold was $54.81. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. Read SEC document |
| May 26, 2026 Filed May 27, 2026 23:14 UTC | Hinge Health, Inc. HNGE · Entity 377 | SaleClass A Common Stock | 8,995 | $53.29 | $479,367.84 |
DisclosureSEC source: 0001783108-26-000018 · form4-05272026_110553.xml · nonDerivative · entry 1 Pursley James · CIK 0001783108 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 787,228 F1 · kind: The sales reported in this line item were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 13, 2025. F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $52.85 and the highest price at which shares were sold was $53.84. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. F3 · balance_after: Includes 781 shares of Class A Common Stock acquired by the Reporting Person on May 15, 2026 pursuant to the Issuer's employee stock purchase plan. Read SEC document |
| May 01, 2026 Filed May 4, 2026 20:07 UTC | Hinge Health, Inc. HNGE · Entity 377 | Tax withholdingClass A Common Stock | 831 | $44.60 | $37,062.60 |
DisclosureSEC source: 0001783108-26-000014 · form4-05042026_080533.xml · nonDerivative · entry 1 Pursley James · CIK 0001783108 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 730,442 F1 · kind: Exempt transaction pursuant to Section 16b-3(e) - payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3. All of the shares reported as disposed of in this Form 4 were relinquished by the Reporting Person and cancelled by the Issuer in exchange for the Issuer's agreement to pay federal and state tax withholding obligations of the Reporting Person resulting from the vesting of restricted stock units. Read SEC document |
| April 29, 2026 Filed May 20, 2026 01:19 UTC | Hinge Health, Inc. HNGE · Entity 377 | GrantClass A Common Stock | 65,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001783108-26-000016 · form4-05202026_010532.xml · nonDerivative · entry 1 Pursley James · CIK 0001783108 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 795,442 F1 · kind: Represents a restricted stock unit ("RSU") award that was acquired through an exempt transaction with the Issuer. Each RSU represents a right to receive one share of the Issuer's Class A Common Stock at the time of vesting for no consideration. Read SEC document |
| April 01, 2026 Filed Apr 1, 2026 20:24 UTC | Hinge Health, Inc. HNGE · Entity 377 | Tax withholdingClass A Common Stock | 831 | $38.56 | $32,043.36 |
DisclosureSEC source: 0001783108-26-000012 · form4-04012026_080425.xml · nonDerivative · entry 1 Pursley James · CIK 0001783108 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 731,273 F1 · kind: Exempt transaction pursuant to Section 16b-3(e) - payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3. All of the shares reported as disposed of in this Form 4 were relinquished by the Reporting Person and cancelled by the Issuer in exchange for the Issuer's agreement to pay federal and state tax withholding obligations of the Reporting Person resulting from the vesting of restricted stock units. Read SEC document |
| March 23, 2026 Filed Mar 24, 2026 23:35 UTC | Hinge Health, Inc. HNGE · Entity 377 | SaleClass A Common Stock | 2,906 | $42.75 | $124,242.54 |
DisclosureSEC source: 0001783108-26-000010 · form4-03242026_110300.xml · nonDerivative · entry 3 Pursley James · CIK 0001783108 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 732,104 F1 · kind: The sales reported in this line item were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 13, 2025. F4 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $42.66 and the highest price at which shares were sold was $42.86. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. Read SEC document |
| March 23, 2026 Filed Mar 24, 2026 23:35 UTC | Hinge Health, Inc. HNGE · Entity 377 | SaleClass A Common Stock | 9,838 | $42.36 | $416,709.15 |
DisclosureSEC source: 0001783108-26-000010 · form4-03242026_110300.xml · nonDerivative · entry 2 Pursley James · CIK 0001783108 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 735,010 F1 · kind: The sales reported in this line item were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 13, 2025. F3 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $41.66 and the highest price at which shares were sold was $42.65. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. Read SEC document |
| March 23, 2026 Filed Mar 24, 2026 23:35 UTC | Hinge Health, Inc. HNGE · Entity 377 | SaleClass A Common Stock | 2,256 | $41.21 | $92,975.63 |
DisclosureSEC source: 0001783108-26-000010 · form4-03242026_110300.xml · nonDerivative · entry 1 Pursley James · CIK 0001783108 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 744,848 F1 · kind: The sales reported in this line item were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 13, 2025. F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $40.66 and the highest price at which shares were sold was $41.62. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. Read SEC document |
| March 01, 2026 Filed Mar 3, 2026 22:27 UTC | Hinge Health, Inc. HNGE · Entity 377 | Tax withholdingClass A Common Stock | 5,127 | $42.76 | $219,230.52 |
DisclosureSEC source: 0001783108-26-000008 · form4-03032026_100302.xml · nonDerivative · entry 1 Pursley James · CIK 0001783108 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 747,104 F1 · kind: Exempt transaction pursuant to Section 16b-3(e) - payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3. All of the shares reported as disposed of in this Form 4 were relinquished by the Reporting Person and cancelled by the Issuer in exchange for the Issuer's agreement to pay federal and state tax withholding obligations of the Reporting Person resulting from the vesting of restricted stock units. Read SEC document |
| February 23, 2026 Filed Feb 24, 2026 21:21 UTC | Hinge Health, Inc. HNGE · Entity 377 | SaleClass A Common Stock | 308 | $40.46 | $12,461.65 |
DisclosureSEC source: 0001783108-26-000006 · form4-02242026_090235.xml · nonDerivative · entry 3 Pursley James · CIK 0001783108 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 752,231 F1 · kind: The sales reported in this line item were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2025. F4 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $40.45 and the highest price at which shares were sold was $40.46. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. Read SEC document |
| February 23, 2026 Filed Feb 24, 2026 21:21 UTC | Hinge Health, Inc. HNGE · Entity 377 | SaleClass A Common Stock | 6,818 | $39.95 | $272,362.74 |
DisclosureSEC source: 0001783108-26-000006 · form4-02242026_090235.xml · nonDerivative · entry 2 Pursley James · CIK 0001783108 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 752,539 F1 · kind: The sales reported in this line item were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2025. F3 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $39.45 and the highest price at which shares were sold was $40.44. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. Read SEC document |
| February 23, 2026 Filed Feb 24, 2026 21:21 UTC | Hinge Health, Inc. HNGE · Entity 377 | SaleClass A Common Stock | 7,874 | $38.76 | $305,159.23 |
DisclosureSEC source: 0001783108-26-000006 · form4-02242026_090235.xml · nonDerivative · entry 1 Pursley James · CIK 0001783108 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 759,357 F1 · kind: The sales reported in this line item were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2025. F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $38.435 and the highest price at which shares were sold was $39.41. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. Read SEC document |
| February 01, 2026 Filed Feb 4, 2026 01:45 UTC | Hinge Health, Inc. HNGE · Entity 377 | Tax withholdingClass A Common Stock | 1,429 | $34.90 | $49,872.10 |
DisclosureSEC source: 0001783108-26-000004 · form4-02042026_010219.xml · nonDerivative · entry 1 Pursley James · CIK 0001783108 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 767,231 F1 · kind: Exempt transaction pursuant to Section 16b-3(e) - payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3. All of the shares reported as disposed of in this Form 4 were relinquished by the Reporting Person and cancelled by the Issuer in exchange for the Issuer's agreement to pay federal and state tax withholding obligations of the Reporting Person resulting from the vesting of restricted stock units. Read SEC document |
| January 01, 2026 Filed Jan 5, 2026 21:34 UTC | Hinge Health, Inc. HNGE · Entity 377 | Tax withholdingClass A Common Stock | 1,118 | $46.45 | $51,931.10 |
DisclosureSEC source: 0001783108-26-000002 · form4-01052026_090146.xml · nonDerivative · entry 1 Pursley James · CIK 0001783108 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 768,660 F1 · kind: Exempt transaction pursuant to Section 16b-3(e) - payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3. All of the shares reported as disposed of in this Form 4 were relinquished by the Reporting Person and cancelled by the Issuer in exchange for the Issuer's agreement to pay federal and state tax withholding obligations of the Reporting Person resulting from the vesting of restricted stock units. Read SEC document |
| December 22, 2025 Filed Dec 23, 2025 21:18 UTC | Hinge Health, Inc. HNGE · Entity 377 | SaleClass A Common Stock | 15,000 | $48.40 | $725,950.50 |
DisclosureSEC source: 0001783108-25-000011 · form4-12232025_091243.xml · nonDerivative · entry 1 Pursley James · CIK 0001783108 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 769,778 F1 · kind: The sales reported in this line item were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2025. F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $47.785 and the highest price at which shares were sold was $48.74. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. Read SEC document |
| December 01, 2025 Filed Dec 1, 2025 21:08 UTC | Hinge Health, Inc. HNGE · Entity 377 | Tax withholdingClass A Common Stock | 5,126 | $48.91 | $250,712.66 |
DisclosureSEC source: 0001783108-25-000009 · form4-12012025_091256.xml · nonDerivative · entry 1 Pursley James · CIK 0001783108 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 784,776 F1 · kind: Exempt transaction pursuant to Section 16b-3(e) - payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3. All of the shares reported as disposed of in this Form 4 were relinquished by the Reporting Person and cancelled by the Issuer in exchange for the Issuer's agreement to pay federal and state tax withholding obligations of the Reporting Person resulting from the vesting of restricted stock units. Read SEC document |
| November 21, 2025 Filed Nov 24, 2025 21:28 UTC | Hinge Health, Inc. HNGE · Entity 377 | SaleClass A Common Stock | 2,954 | $46.09 | $136,145.43 |
DisclosureSEC source: 0001783108-25-000007 · form4-11242025_091133.xml · nonDerivative · entry 3 Pursley James · CIK 0001783108 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 789,902 F1 · kind: The sales reported in this line item were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2025. F4 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $46.01 and the highest price at which shares were sold was $46.21. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. Read SEC document |
| November 21, 2025 Filed Nov 24, 2025 21:28 UTC | Hinge Health, Inc. HNGE · Entity 377 | SaleClass A Common Stock | 9,332 | $45.75 | $426,965.13 |
DisclosureSEC source: 0001783108-25-000007 · form4-11242025_091133.xml · nonDerivative · entry 2 Pursley James · CIK 0001783108 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 792,856 F1 · kind: The sales reported in this line item were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2025. F3 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $45.01 and the highest price at which shares were sold was $46.00. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. Read SEC document |
| November 21, 2025 Filed Nov 24, 2025 21:28 UTC | Hinge Health, Inc. HNGE · Entity 377 | SaleClass A Common Stock | 2,714 | $44.35 | $120,376.21 |
DisclosureSEC source: 0001783108-25-000007 · form4-11242025_091133.xml · nonDerivative · entry 1 Pursley James · CIK 0001783108 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 802,190 F1 · kind: The sales reported in this line item were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2025. F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $43.96 and the highest price at which shares were sold was $44.94. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. Read SEC document |
| November 18, 2025 Filed Nov 19, 2025 21:52 UTC | Hinge Health, Inc. HNGE · Entity 377 | Tax withholdingClass A Common Stock | 15,977 | $40.84 | $652,500.68 |
DisclosureSEC source: 0001783108-25-000005 · form4-11192025_091153.xml · nonDerivative · entry 1 Pursley James · CIK 0001783108 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 804,904 F1 · kind: Exempt transaction pursuant to Section 16b-3(e) - payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3. All of the shares reported as disposed of in this Form 4 were relinquished by the Reporting Person and cancelled by the Issuer in exchange for the Issuer's agreement to pay federal and state tax withholding obligations of the Reporting Person resulting from the vesting of restricted stock units. F2 · balance_after: Includes 781 shares of Class A Common Stock acquired by the Reporting Person on November 14, 2025 pursuant to the Issuer's employee stock purchase plan. Read SEC document |
| May 23, 2025 Filed May 23, 2025 21:21 UTC | Hinge Health, Inc. HNGE · Entity 377 | OtherClass A Common Stock | 820,100 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-077107 · ownership.xml · nonDerivative · entry 4 Pursley James · CIK 0001783108 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 820,100 F3 · kind: Immediately prior to the completion of the Issuer's initial public offering, each share of Common Stock (other than those held by the Issuer's founders and certain related individuals), including shares of Common Stock underlying RSU awards, was reclassified into one share of Class A Common Stock in an exempt transaction pursuant to Rule 16b-7. F3 · price: Immediately prior to the completion of the Issuer's initial public offering, each share of Common Stock (other than those held by the Issuer's founders and certain related individuals), including shares of Common Stock underlying RSU awards, was reclassified into one share of Class A Common Stock in an exempt transaction pursuant to Rule 16b-7. F4 · balance_after: Includes 215,417 RSUs, which vest in accordance with the terms of the applicable awards. Each RSU represents a contingent right to receive one share of Class A Common Stock. Read SEC document |
| May 23, 2025 Filed May 23, 2025 21:21 UTC | Hinge Health, Inc. HNGE · Entity 377 | OtherCommon Stock | 820,100 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-077107 · ownership.xml · nonDerivative · entry 3 Pursley James · CIK 0001783108 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F3 · kind: Immediately prior to the completion of the Issuer's initial public offering, each share of Common Stock (other than those held by the Issuer's founders and certain related individuals), including shares of Common Stock underlying RSU awards, was reclassified into one share of Class A Common Stock in an exempt transaction pursuant to Rule 16b-7. F3 · price: Immediately prior to the completion of the Issuer's initial public offering, each share of Common Stock (other than those held by the Issuer's founders and certain related individuals), including shares of Common Stock underlying RSU awards, was reclassified into one share of Class A Common Stock in an exempt transaction pursuant to Rule 16b-7. Read SEC document |
| May 21, 2025 Filed May 23, 2025 21:21 UTC | Hinge Health, Inc. HNGE · Entity 377 | Tax withholdingCommon Stock | 445,646 | $32.00 | $14,260,672.00 |
DisclosureSEC source: 0000950170-25-077107 · ownership.xml · nonDerivative · entry 2 Pursley James · CIK 0001783108 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 820,100 Read SEC document |
| April 29, 2025 Filed May 23, 2025 21:21 UTC | Hinge Health, Inc. HNGE · Entity 377 | GrantCommon Stock | 96,875 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-077107 · ownership.xml · nonDerivative · entry 1 Pursley James · CIK 0001783108 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,265,746 F1 · shares: Reflects an award of restricted stock units ("RSUs"), which vests as to 3.125% of the total award each quarter for the first two years, and as to 9.375% of the total award each quarter thereafter until fully vested at the fourth anniversary of the vesting commencement date. Each RSU represents a contingent right to receive one share of Class A Common Stock following the reclassification of the Issuer's Common Stock. F2 · balance_after: These securities were previously reported on a Form 3 filed by the Reporting Person. Read SEC document |
| October 30, 2020 Filed Oct 30, 2020 21:21 UTC | Livongo Health, Inc. LVGO · Entity 145566 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 100,000 | Not disclosed Strike: $3.62 | Not disclosed |
DisclosureSEC source: 0001639225-20-000064 · wf-form4_160409289833502.xml · derivative · entry 6 Pursley James · CIK 0001783108 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires 2028-06-18 F4 · price: The "Equity Award Adjustment Ratio" means the quotient determined by dividing (i) the volume weighted average closing price of the Issuer's common stock on the four trading days ending on October 29, 2020 by (ii) the volume weighted average closing price of Teladoc common stock on the four trading days beginning on October 29, 2020. F6 · price: Pursuant to the Merger Agreement, each outstanding stock option of the Issuer, whether vested or unvested, was converted into an option to purchase a number of shares of Teladoc common stock equal to the product of (i) the number of shares of the Issuer's common stock subject to such Issuer stock option immediately prior to the effective time of the merger and (ii) the Equity Award Adjustment Ratio (rounded down to the nearest whole share of Teladoc common stock on an award-by-award basis), with an exercise price equal to the quotient of (x) the exercise price of such Issuer stock option and (y) the Equity Award Adjustment Ratio (rounded up to the nearest whole cent), subject to the same terms and conditions as were applicable to such Issuer stock option immediately prior to the effective time of the merger (including applicable vesting conditions). F9 · derivative.exercise_date: One-fourth of the shares subject to the option vested on June 19, 2019 and 1/48 of the shares vest monthly thereafter. Read SEC document |
| October 30, 2020 Filed Oct 30, 2020 21:21 UTC | Livongo Health, Inc. LVGO · Entity 145566 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 120,000 | Not disclosed Strike: $1.88 | Not disclosed |
DisclosureSEC source: 0001639225-20-000064 · wf-form4_160409289833502.xml · derivative · entry 5 Pursley James · CIK 0001783108 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 120,000 shares Expires 2027-12-03 F4 · price: The "Equity Award Adjustment Ratio" means the quotient determined by dividing (i) the volume weighted average closing price of the Issuer's common stock on the four trading days ending on October 29, 2020 by (ii) the volume weighted average closing price of Teladoc common stock on the four trading days beginning on October 29, 2020. F6 · price: Pursuant to the Merger Agreement, each outstanding stock option of the Issuer, whether vested or unvested, was converted into an option to purchase a number of shares of Teladoc common stock equal to the product of (i) the number of shares of the Issuer's common stock subject to such Issuer stock option immediately prior to the effective time of the merger and (ii) the Equity Award Adjustment Ratio (rounded down to the nearest whole share of Teladoc common stock on an award-by-award basis), with an exercise price equal to the quotient of (x) the exercise price of such Issuer stock option and (y) the Equity Award Adjustment Ratio (rounded up to the nearest whole cent), subject to the same terms and conditions as were applicable to such Issuer stock option immediately prior to the effective time of the merger (including applicable vesting conditions). F8 · derivative.exercise_date: One-fourth of the shares subject to the option vested on December 4, 2018 and 1/48 of the shares vest monthly thereafter. Read SEC document |
| October 30, 2020 Filed Oct 30, 2020 21:21 UTC | Livongo Health, Inc. LVGO · Entity 145566 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 125,000 | Not disclosed Strike: $1.38 | Not disclosed |
DisclosureSEC source: 0001639225-20-000064 · wf-form4_160409289833502.xml · derivative · entry 4 Pursley James · CIK 0001783108 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 125,000 shares Expires 2026-11-15 F4 · price: The "Equity Award Adjustment Ratio" means the quotient determined by dividing (i) the volume weighted average closing price of the Issuer's common stock on the four trading days ending on October 29, 2020 by (ii) the volume weighted average closing price of Teladoc common stock on the four trading days beginning on October 29, 2020. F6 · price: Pursuant to the Merger Agreement, each outstanding stock option of the Issuer, whether vested or unvested, was converted into an option to purchase a number of shares of Teladoc common stock equal to the product of (i) the number of shares of the Issuer's common stock subject to such Issuer stock option immediately prior to the effective time of the merger and (ii) the Equity Award Adjustment Ratio (rounded down to the nearest whole share of Teladoc common stock on an award-by-award basis), with an exercise price equal to the quotient of (x) the exercise price of such Issuer stock option and (y) the Equity Award Adjustment Ratio (rounded up to the nearest whole cent), subject to the same terms and conditions as were applicable to such Issuer stock option immediately prior to the effective time of the merger (including applicable vesting conditions). F7 · derivative.exercise_date: One-fourth of the shares subject to the option vested on November 16, 2017 and 1/48 of the shares vest monthly thereafter. Read SEC document |
| October 30, 2020 Filed Oct 30, 2020 21:21 UTC | Livongo Health, Inc. LVGO · Entity 145566 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 50,000 | Not disclosed Strike: $0.80 | Not disclosed |
DisclosureSEC source: 0001639225-20-000064 · wf-form4_160409289833502.xml · derivative · entry 3 Pursley James · CIK 0001783108 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2026-02-17 F4 · price: The "Equity Award Adjustment Ratio" means the quotient determined by dividing (i) the volume weighted average closing price of the Issuer's common stock on the four trading days ending on October 29, 2020 by (ii) the volume weighted average closing price of Teladoc common stock on the four trading days beginning on October 29, 2020. F6 · price: Pursuant to the Merger Agreement, each outstanding stock option of the Issuer, whether vested or unvested, was converted into an option to purchase a number of shares of Teladoc common stock equal to the product of (i) the number of shares of the Issuer's common stock subject to such Issuer stock option immediately prior to the effective time of the merger and (ii) the Equity Award Adjustment Ratio (rounded down to the nearest whole share of Teladoc common stock on an award-by-award basis), with an exercise price equal to the quotient of (x) the exercise price of such Issuer stock option and (y) the Equity Award Adjustment Ratio (rounded up to the nearest whole cent), subject to the same terms and conditions as were applicable to such Issuer stock option immediately prior to the effective time of the merger (including applicable vesting conditions). F5 · derivative.exercise_date: Shares subject to the option are fully vested and immediately exercisable. Read SEC document |
| October 30, 2020 Filed Oct 30, 2020 21:21 UTC | Livongo Health, Inc. LVGO · Entity 145566 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 105,572 | Not disclosed Strike: $0.80 | Not disclosed |
DisclosureSEC source: 0001639225-20-000064 · wf-form4_160409289833502.xml · derivative · entry 2 Pursley James · CIK 0001783108 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 105,572 shares Expires 2025-12-10 F4 · price: The "Equity Award Adjustment Ratio" means the quotient determined by dividing (i) the volume weighted average closing price of the Issuer's common stock on the four trading days ending on October 29, 2020 by (ii) the volume weighted average closing price of Teladoc common stock on the four trading days beginning on October 29, 2020. F6 · price: Pursuant to the Merger Agreement, each outstanding stock option of the Issuer, whether vested or unvested, was converted into an option to purchase a number of shares of Teladoc common stock equal to the product of (i) the number of shares of the Issuer's common stock subject to such Issuer stock option immediately prior to the effective time of the merger and (ii) the Equity Award Adjustment Ratio (rounded down to the nearest whole share of Teladoc common stock on an award-by-award basis), with an exercise price equal to the quotient of (x) the exercise price of such Issuer stock option and (y) the Equity Award Adjustment Ratio (rounded up to the nearest whole cent), subject to the same terms and conditions as were applicable to such Issuer stock option immediately prior to the effective time of the merger (including applicable vesting conditions). F5 · derivative.exercise_date: Shares subject to the option are fully vested and immediately exercisable. Read SEC document |
| October 30, 2020 Filed Oct 30, 2020 21:21 UTC | Livongo Health, Inc. LVGO · Entity 145566 | Disposition to issuerCommon Stock | 73,294 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001639225-20-000064 · wf-form4_160409289833502.xml · nonDerivative · entry 1 Pursley James · CIK 0001783108 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Includes 21,537 restricted stock units ("RSUs"). F2 · price: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 5, 2020, by and among the Issuer, Teladoc Health, Inc. ("Teladoc"), and Tempranillo Merger Sub, Inc., a wholly owned subsidiary of Teladoc, each share of the Issuer's common stock was converted into the right to receive 0.5920 of a share of Teladoc common stock and $4.24 in cash, without interest, together with cash in lieu of fractional shares (if any). F3 · price: Pursuant to the Merger Agreement, each outstanding RSU award of the Issuer was converted into a number of RSUs with respect to a number of shares of Teladoc common stock equal to the product of (i) the number of shares of the Issuer's common stock subject to such RSU award immediately prior to the effective time of the merger and (ii) the Equity Award Adjustment Ratio (as defined below) (rounded down to the nearest whole share of Teladoc common stock on an award-by-award basis), subject to the same terms and conditions as were applicable to such Issuer RSU immediately prior to the effective time of the merger (including applicable vesting conditions). F4 · price: The "Equity Award Adjustment Ratio" means the quotient determined by dividing (i) the volume weighted average closing price of the Issuer's common stock on the four trading days ending on October 29, 2020 by (ii) the volume weighted average closing price of Teladoc common stock on the four trading days beginning on October 29, 2020. Read SEC document |
| September 04, 2020 Filed Sep 5, 2020 01:14 UTC | Livongo Health, Inc. LVGO · Entity 145566 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 19,428 | $0.00 Strike: $0.80 | $0.00 |
DisclosureSEC source: 0001209191-20-049683 · doc4.xml · derivative · entry 8 Pursley James · CIK 0001783108 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,572 Underlying: Common Stock · 19,428 shares Expires 2025-12-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Shares subject to the option are fully vested and immediately exercisable. Read SEC document |
| September 04, 2020 Filed Sep 5, 2020 01:14 UTC | Livongo Health, Inc. LVGO · Entity 145566 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 5,429 | $0.00 Strike: $0.36 | $0.00 |
DisclosureSEC source: 0001209191-20-049683 · doc4.xml · derivative · entry 7 Pursley James · CIK 0001783108 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,429 shares Expires 2024-12-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Shares subject to the option are fully vested and immediately exercisable. Read SEC document |
| September 04, 2020 Filed Sep 5, 2020 01:14 UTC | Livongo Health, Inc. LVGO · Entity 145566 | SaleCommon Stock | 341 | $129.03 | $44,000.66 |
DisclosureSEC source: 0001209191-20-049683 · doc4.xml · nonDerivative · entry 6 Pursley James · CIK 0001783108 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,294 F1 · kind: On August 5, 2020, the Issuer entered into an Agreement and Plan of Merger with Teladoc Health, Inc. ("Teladoc") and Tempranillo Merger Sub, Inc., a wholly-owned subsidiary of Teladoc ("Merger Sub"), pursuant to which Merger Sub will merge with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Teladoc (the "Merger"). Pursuant to the terms of the Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2019 (the "Trading Plan"), all sales pursuant to the Trading Plan were automatically suspended following the public announcement of the Merger without any action by the reporting person, and the Trading Plan was subsequently terminated. The number of shares sold and reported on this form is consistent with the number of shares that would have been sold by the reporting person pursuant to the Trading Plan had the Trading Plan not been suspended in connection with the Merger. F2 · kind: Following the sales reported on this form, the reporting person continues to hold over 85% of the shares of the Issuer's common stock and vested stock options held immediately prior to such sales. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $128.77 to $129.16, inclusive. Read SEC document |
| September 04, 2020 Filed Sep 5, 2020 01:14 UTC | Livongo Health, Inc. LVGO · Entity 145566 | SaleCommon Stock | 940 | $128.00 | $120,319.25 |
DisclosureSEC source: 0001209191-20-049683 · doc4.xml · nonDerivative · entry 5 Pursley James · CIK 0001783108 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,635 F1 · kind: On August 5, 2020, the Issuer entered into an Agreement and Plan of Merger with Teladoc Health, Inc. ("Teladoc") and Tempranillo Merger Sub, Inc., a wholly-owned subsidiary of Teladoc ("Merger Sub"), pursuant to which Merger Sub will merge with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Teladoc (the "Merger"). Pursuant to the terms of the Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2019 (the "Trading Plan"), all sales pursuant to the Trading Plan were automatically suspended following the public announcement of the Merger without any action by the reporting person, and the Trading Plan was subsequently terminated. The number of shares sold and reported on this form is consistent with the number of shares that would have been sold by the reporting person pursuant to the Trading Plan had the Trading Plan not been suspended in connection with the Merger. F2 · kind: Following the sales reported on this form, the reporting person continues to hold over 85% of the shares of the Issuer's common stock and vested stock options held immediately prior to such sales. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $127.58 to $128.49, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3) and (4) to this Form 4. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.